Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

NCT00849667 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1100

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Ovarian Cancer

Interventions

DRUG: Farletuzumab
DRUG: Carboplatin
DRUG: Taxane
DRUG: Farletuzumab-matched placebo

Sponsor

Morphotek

Collaborators

[object Object]